title: [Congenital toxoplasmosis and seroconversion at the end of pregnancy: clinical observations].
abstract: We report seven cases of subclinical congenital toxoplasmosis secondary to maternal primary infections. Mothers were infected between two and four weeks prior to delivery. The diagnostic criteria of congenital infections included: IgM antibody (Ab) (1 case); IgM and IgA Ab (1 case); a real IgG seroconversion in the neonatal and postnatal samples (3 cases); persistence of IgG Ab beyond 6 months post-delivery (2 cases). A treatment was initiated, including a combination of pyrimethamine + sulfadiazine (6 cases); trimethoprim + sulfamethoxazole (1 case). This retrospective study suggests that it is important to screen the non-immune pregnant women until delivery. We confirmed the usefulness of a combination of isotypes of antibodies for the accurate assessment of congenital infection. Finally, infected infants have to be treated and monitored clinically and immunologically during the first year of life.
authors.affiliation: Service de Biologie Clinique, Clinique Saint-Pierre, Ottignies.
authors.forename: V
authors.initials: V
authors.lastname: Luyasu
authors.forename: O
authors.initials: O
authors.lastname: Bauraind
authors.forename: P
authors.initials: P
authors.lastname: Bernard
authors.forename: Y
authors.initials: Y
authors.lastname: Bietlot
authors.forename: C
authors.initials: C
authors.lastname: Brasseur
authors.forename: J
authors.initials: J
authors.lastname: Englebert
authors.forename: L
authors.initials: L
authors.lastname: Fiasse
authors.forename: O
authors.initials: O
authors.lastname: Givron
authors.forename: E
authors.initials: E
authors.lastname: Longueville
authors.forename: J L
authors.initials: JL
authors.lastname: Melard
authors.forename: M
authors.initials: M
authors.lastname: Michel
authors.forename: M
authors.initials: M
authors.lastname: Wacquez
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000913:Antibodies, Protozoan / Q000302:isolation & purification*; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000302:isolation & purification; D007074:Immunoglobulin G / Q000302:isolation & purification; D007231:Infant, Newborn; D011247:Pregnancy; D015597:Pregnancy Complications, Parasitic / Q000188:drug therapy / Q000276:immunology*; D012189:Retrospective Studies; D015572:Spiramycin / Q000627:therapeutic use; D014123:Toxoplasmosis / Q000188:drug therapy / Q000276:immunology*; D014125:Toxoplasmosis, Congenital / Q000188:drug therapy / Q000276:immunology*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D000913:Antibodies, Protozoan; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D015572:Spiramycin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
vernacular_title: Toxoplasmoses congénitales et séroconversions de fin de grossesse: observations cliniques.